Curing ALL Diseases & Enhancing Human Potential

Drug Discovery with Feras

quote
"The Availability of Diseases and Chemicals Data, along with the Accelerated Revolution in Drug Discovery with AI will help in finding cure for all diseases but also in enhancing human potential, we have built this platforms to help pharmaceutical companies manufacture new drugs and enhance human potentials, making the new frontiers of health available for the masses "
- Feras Naser

New Generic Drugs

Ozempic (Semaglutide)

A GLP-1 receptor agonist used for Type 2 Diabetes (and Wegovy for weight loss). It mimics a hormone that triggers insulin release.

Patent Expiry 
2026 (Canada, China, India, Brazil); Early 2030s (US/EU).

Market Size

~$26B in 2024 (Global).

Manufacturing Manual & Instructions (Produced by AI) 

Pharmaceutical Companies Comment

Other Notes
Classified as a “Biologic” in many regions, making biosimilar production complex.

Discovery and Research 

Feras Naser

Eliquis (Apixaban)

An oral anticoagulant (blood thinner) that prevents stroke and blood clots in patients with atrial fibrillation.

Patent Expiry 
April 2028 (US); May 2026 (EU).

Market Size

~$14B annual sales (2025 peak).

Manufacturing Manual & Instructions (Produced by AI) 

Pharmaceutical Companies Comment

Other Notes
Bristol Myers Squibb (BMS) and Pfizer used “follow-on” patents to delay generics until 2028.

Important Documents 

Drug Establishment Registration | Manufacturing License |GMP Certificate (Good Manufacturing Practice) | DEA Registration | ANDA | DMF (Drug Master File) | Site Master File (SMF) | Stability Study Reports | Batch Manufacturing Records (BMR)

Discovery and Research 

Feras Naser

Humira (Adalimumab)

A TNF blocker used to treat autoimmune diseases like Rheumatoid Arthritis, Crohn’s Disease, and Psoriasis.

Patent Expiry 
Expired (2018 EU, 2023 US).

Market Size

~$21B (2022); declining to ~$4B by 2030.

Manufacturing Manual & Instructions (Produced by AI) 

Pharmaceutical Companies Comment

Other Notes
One of the most successful drugs in history; now faces massive competition from biosimilars (Amjevita, etc.).

Discovery and Research 

Feras Naser

Copaxone (Glatiramer Acetate)

An immunomodulator used to reduce the frequency of relapses in Multiple Sclerosis (MS).

Patent Expiry 
August 2030 (specific dosage patents).

Market Size

~$4.7B peak; now eroded by generics.

Manufacturing Manual & Instructions (Produced by AI) 

Pharmaceutical Companies Comment

Other Notes
 eroded by generics.It is a “Non-Biological Complex Drug” (NBCD), which is harder to replicate than standard chemical generics

Discovery and Research 

Feras Naser

Januvia (Sitagliptin)

A DPP-4 inhibitor used to improve blood sugar control in adults with Type 2 Diabetes.

Patent Expiry 
May 2026 (Pediatric extension to May 2027). 

Market Size

~$4B (Global sales)

Manufacturing Manual & Instructions (Produced by AI) 

Pharmaceutical Companies Comment

Other Notes
Merck often pairs this with Metformin (Janumet); Janumet’s patent expires later (2029).

Discovery and Research 

Feras Naser